Relevant information is provided on the website of the organization.

"Pfizer's oral antiviral (a combination of nirmatrelvir and ritonavir tablets) is strongly recommended for patients with non-severe forms of COVID-19, who are at the highest risk of developing severe illness and hospitalization," the report said.

As specified, the recommendation is based on new data from two randomized controlled trials involving 3078 patients.

Earlier, Pfizer reported that Paxlovid coronavirus pills showed efficacy against the Omicron strain of coronavirus in three laboratory tests.

The US medical regulator, the FDA, has also approved Pfizer's coronavirus pill for emergency use.